Oppenheimer Sticks to Their Hold Rating for Cartesian Therapeutics (RNAC)
Buy Rating Affirmed for Cartesian Therapeutics Amid Clinical Success and Strengthened Financials
Cartesian Therapeutics Analyst Ratings
TD Cowen Initiates Cartesian Therapeutics(RNAC.US) With Buy Rating
Cartesian Therapeutics Analyst Ratings
Cartesian Therapeutics Analyst Ratings
Canaccord Genuity Maintains Buy on Cartesian Therapeutics, Raises Price Target to $43
Buy Rating Affirmed for Cartesian Therapeutics on Descartes-08's Promising Clinical Trial Results
Optimistic Buy Rating for Cartesian Therapeutics Ahead of Phase IIb Trial Results
Cartesian Therapeutics Analyst Ratings
Cartesian Therapeutics Analyst Ratings
Cartesian Therapeutics Analyst Ratings
Cartesian Therapeutics Analyst Ratings
Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target
Cartesian Therapeutics Analyst Ratings
Buy Rating Affirmed for Cartesian Therapeutics Amidst Promising Clinical Advancements and Strategic Positioning
Cartesian Therapeutics Analyst Ratings
Buy Rating Affirmed for Cartesian Therapeutics on Strong Clinical Progress and Strategic Expansion
Cartesian Therapeutics Analyst Ratings
Cartesian Therapeutics Analyst Ratings